-
February 1, 2019
The Third Quarter of FY2018 (April 2018- December 2018) -
February 1, 2019
R&D Pipeline as of February 2019 -
November 6, 2018
The Second Quarter of FY2018 (April 2018 - September 2018) -
September 28, 2018
Annual Report 2018 -
July 31, 2018
The First Quarter of FY2018 (April 2018 - June 2018)
-
November 27, 2018
Launch of "P-TOL® Granules" for the Treatment of Hyperphosphatemia -
November 20, 2018
Launch of "Beova® Tablets 50mg" for the Treatment of Overactive Bladder -
October 30, 2018
Announcement of in-licensing of technology related to a small molecule tyrosine kinase inhibitor fostamatinib -
September 21, 2018
Kyorin Receives Marketing Approval in Japan for "Beova® Tablets 50mg" for the Treatment of Overactive Bladder -
May 30, 2018
Kissei Announces Negative Topline Results from the additional phase III Clinical Trial evaluating "KPS-0373 (Development Code)" for the Treatment of Spinocerebellar Ataxia
